PRESS RELEASE
News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results confirming the efficacy of Telomir-1 in age-reversal science. The study demonstrates significant age-reversal effects in model organisms, supporting longevity and improved healthspan -
-
PRESS RELEASE
Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Nextech3D.AI announces spin-out Toggle.ai rebrand as FOTOgpt.ai, focusing on AI-powered photography. API plugin launch in December 2024, standalone app in Q1 2025, revolutionizing photo editing with advanced AI technology -
PRESS RELEASE
Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Clean Air Metals reports positive results from the Ambient Noise Tomography Survey conducted over the Escape conduit, indicating a potential one-kilometer down-plunge extension of the deposit. Further geophysics planned in 2025 for high-grade target areas -
PRESS RELEASE
Electrovaya Receives Follow On Orders for High Voltage Battery Systems from Global Aerospace and Defense Company Following Extensive Testing
Electrovaya's Infinity-HV battery systems demonstrate exceptional performance and reliability for mission critical defense applications, leading to a follow-on order. The Company plans to increase manufacturing capacity in New York -
PRESS RELEASE
Interactive Strength Inc. (Nasdaq: TRNR) Board of Directors Approves Bitcoin as Treasury Reserve Asset
Interactive Strength Inc. (NASDAQ: TRNR) announces the approval of a maximum $5 million Bitcoin purchase by its Board of Directors and plans to accept digital currency payments to enhance shareholder value and strengthen treasury -
-
PRESS RELEASE
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven. Shield Therapeutics increasing physician awareness for ACCRUFeR® sales traction -
